Patents by Inventor Anthony Ling

Anthony Ling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNE EFFECTOR CELL COVALENT IMMUNE RECRUITING (CIR) MOLECULES AND METHODS AND USES THEREOF
    Publication number: 20240083971
    Abstract: The present description relates to covalent immune recruiters (CIRs) comprising an Fc receptor targeting domain (FTD), a covalent binding group (CBG), and a target binding domain (TBD), wherein on binding of the FTD to a cognate Fc receptor, the CBG forms a covalent bond with an amino acid in the Fc receptor. The present description also includes functionalized cells modified by covalent binding of the CIR, methods and uses thereof, for example, methods of functionalizing cells, and methods and uses of such cells for recognition of target cells.
    Type: Application
    Filed: August 15, 2023
    Publication date: March 14, 2024
    Inventors: Anthony Rullo, Yonghong Wan, Eden Kapcan, Zi Ling Yang
  • Glucagon antagonists/inverse agonists
    Publication number: 20050203108
    Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
    Type: Application
    Filed: November 3, 2004
    Publication date: September 15, 2005
    Inventors: Jesper Lau, Peter Madsen, Christian Sams, Carsten Behrens, Josef Vagner, Inge Christensen, Behrend Lundt, Ulla Sidelmann, Henning Thogersen, Anthony Ling, Michael Plewe, Larry Truesdale, Anker Jogensen, Janos Kodra, Shenghua Shi
  • Glucagon antagonists/inverse agonists
    Publication number: 20040127560
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: November 13, 2003
    Publication date: July 1, 2004
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling
  • Glucagon antagonists/inverse agonists
    Patent number: 6706744
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Grant
    Filed: November 16, 2001
    Date of Patent: March 16, 2004
    Assignee: Novo Nordisk A/S
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling
  • Glucagon antagonists/inverse agonists
    Patent number: 6613942
    Abstract: Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof are disclosed. The compounds act to antagonize the action of the glucagon peptide hormone.
    Type: Grant
    Filed: December 23, 1998
    Date of Patent: September 2, 2003
    Assignee: Novo Nordisk A/S
    Inventors: Anthony Ling, Vlad Gregor, Javier Gonzalez, Yufeng Hong, Dan Kiel, Atsuo Kuki, Shenghua Shi, Lars Naerum, Peter Madsen, Christian Sams, Jesper Lau, Michael Bruno Plewe, Jun Feng, Min Teng, Michael David Johnson, Kimberly Ann Teston, Ulla Grove Sidelmann, Lotte Bjerre Knudsen
  • Glucagon antagonists/inverse agonists
    Publication number: 20030065031
    Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.
    Type: Application
    Filed: November 16, 2001
    Publication date: April 3, 2003
    Inventors: Peter Madsen, Jesper Lau, Anthony Ling